CME Group Inc. (NASDAQ:CME) Shares Sold by First National Trust Co

First National Trust Co decreased its stake in shares of CME Group Inc. (NASDAQ:CME) by 3.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 21,473 shares of the financial services provider’s stock after selling 684 shares during the period. First National Trust Co’s holdings in CME Group were worth $4,738,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC increased its holdings in shares of CME Group by 21.2% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 48,205 shares of the financial services provider’s stock valued at $9,477,000 after acquiring an additional 8,443 shares during the last quarter. Cetera Investment Advisers increased its stake in CME Group by 429.1% during the first quarter. Cetera Investment Advisers now owns 47,521 shares of the financial services provider’s stock valued at $10,231,000 after purchasing an additional 38,540 shares during the last quarter. Brookstone Capital Management raised its holdings in shares of CME Group by 12.2% during the second quarter. Brookstone Capital Management now owns 30,555 shares of the financial services provider’s stock worth $6,156,000 after purchasing an additional 3,325 shares during the period. TD Asset Management Inc lifted its position in shares of CME Group by 16.1% in the 1st quarter. TD Asset Management Inc now owns 371,849 shares of the financial services provider’s stock worth $80,055,000 after buying an additional 51,689 shares during the last quarter. Finally, Epoch Investment Partners Inc. boosted its holdings in shares of CME Group by 4.7% in the 1st quarter. Epoch Investment Partners Inc. now owns 99,947 shares of the financial services provider’s stock valued at $21,518,000 after buying an additional 4,454 shares during the period. 87.75% of the stock is owned by institutional investors.

CME Group Stock Performance

CME opened at $225.93 on Tuesday. CME Group Inc. has a fifty-two week low of $190.70 and a fifty-two week high of $230.36. The firm has a market cap of $81.36 billion, a PE ratio of 23.76, a P/E/G ratio of 5.68 and a beta of 0.55. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $221.92 and a 200-day simple moving average of $209.93.

CME Group (NASDAQ:CME) last released its earnings results on Wednesday, October 23rd. The financial services provider reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.03. CME Group had a net margin of 57.34% and a return on equity of 13.39%. The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same period last year, the firm posted $2.25 earnings per share. The firm’s quarterly revenue was up 18.4% compared to the same quarter last year. As a group, equities analysts predict that CME Group Inc. will post 10.23 EPS for the current fiscal year.

CME Group Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 27th. Investors of record on Monday, December 9th will be given a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.04%. The ex-dividend date of this dividend is Monday, December 9th. CME Group’s payout ratio is 48.37%.

Insider Buying and Selling

In related news, Director Martin J. Gepsman sold 400 shares of the firm’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $222.92, for a total transaction of $89,168.00. Following the completion of the sale, the director now directly owns 25,067 shares in the company, valued at approximately $5,587,935.64. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, Director Bryan T. Durkin sold 7,593 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $214.59, for a total value of $1,629,381.87. Following the transaction, the director now owns 55,607 shares in the company, valued at approximately $11,932,706.13. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Martin J. Gepsman sold 400 shares of the stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $222.92, for a total value of $89,168.00. Following the transaction, the director now directly owns 25,067 shares in the company, valued at approximately $5,587,935.64. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,621 shares of company stock valued at $3,441,063. Corporate insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on CME. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of CME Group from $227.00 to $226.00 and set a “hold” rating on the stock in a research note on Monday. Citigroup raised their target price on CME Group from $250.00 to $255.00 and gave the company a “buy” rating in a research note on Thursday, October 24th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $235.00 price objective on shares of CME Group in a report on Thursday, October 24th. JPMorgan Chase & Co. raised their price target on shares of CME Group from $187.00 to $191.00 and gave the company an “underweight” rating in a research note on Thursday, July 25th. Finally, Keefe, Bruyette & Woods increased their price objective on CME Group from $212.00 to $213.00 and gave the stock a “market perform” rating in a report on Thursday, July 25th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, CME Group currently has a consensus rating of “Hold” and an average price target of $224.47.

CME Group Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.